Literature DB >> 30108322

Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children.

Michaël Philippe1,2, Michael Neely3, Teresa Rushing4, Yves Bertrand5, Nathalie Bleyzac6,7, Sylvain Goutelle8,9,10.   

Abstract

Veno-occlusive disease (VOD) is a severe adverse reaction to busulfan-containing regimens used in the preparation of children for hematopoietic stem cell transplantation (HSCT). We conducted a retrospective analysis of data to examine determinants of VOD in children who received IV busulfan for HSCT conditioning. Busulfan PK parameters as well as various indices (maximal concentration-Cmax, area under the concentration-time curve-AUC) were estimated using a validated Bayesian approach. The influence of available PK, demographic, and clinical variables on the incidence of VOD was evaluated by using logistic regression and classification and regression tree (CART) analyses. Among the 293 patients included, the mean age was 6.5 years and the mean actual body weight was 26.3 kg. The incidence of VOD was 25.6%. Busulfan Cmax as well as weight <9 kg or age <3 years were identified as independent predictors of VOD in logistic regression analysis. CART analysis identified busulfan Cmax over the entire regimen as the strongest predictor of VOD. This study suggests that busulfan-associated VOD is in part a concentration-dependent reaction. In addition, the youngest children showed the highest risk of VOD. These findings may have important implications for busulfan dosing and therapeutic drug monitoring practice in HSCT children.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30108322     DOI: 10.1038/s41409-018-0281-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study.

Authors:  Xiaohuan Du; Chenrong Huang; Ling Xue; Zheng Jiao; Min Zhu; Jie Li; Jun Lu; Peifang Xiao; Xuemei Zhou; Chenmei Mao; Zengyan Zhu; Ji Dong; Xiaoxue Liu; Zhiyao Chen; Shichao Zhang; Yiduo Ding; Shaoyan Hu; Liyan Miao
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

2.  Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring.

Authors:  Duan-Fang Shao; Jun-Hui Li; Tao Hu; Zhao-Xia Zhang; Lei Zhang; Juan-Juan Li; Jing Cao; Shun-Qiao Feng; Rui-Hong Tang; Di-Xiao Zhong; Ze-Liang Song; Mei Yue; Meng-Ze Hu; Li-Tian Xuan; Meng-Na Zhai; Hai-Feng Zhang; Xiang-Yan Wang; Xiao-Dong Shi; Rong Liu
Journal:  Bone Marrow Transplant       Date:  2022-01-17       Impact factor: 5.174

Review 3.  Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Stefanie Hennig
Journal:  Clin Pharmacokinet       Date:  2020-10-30       Impact factor: 6.447

4.  Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.

Authors:  Claire Seydoux; Raphael Battegay; Joerg Halter; Dominik Heim; Katharina M Rentsch; Jakob R Passweg; Michael Medinger
Journal:  Bone Marrow Transplant       Date:  2022-03-31       Impact factor: 5.174

5.  NRF2 -617 C/A Polymorphism Impacts Proinflammatory Cytokine Levels, Survival, and Transplant-Related Mortality After Hematopoietic Stem Cell Transplantation in Adult Patients Receiving Busulfan-Based Conditioning Regimens.

Authors:  Jingjing Huang; Chenxia Hao; Ziwei Li; Ling Wang; Jieling Jiang; Wei Tang; Lining Wang; Weixia Zhang; Jiong Hu; Wanhua Yang
Journal:  Front Pharmacol       Date:  2020-12-15       Impact factor: 5.810

6.  Interest of the preventive and curative use of defibrotide on the occurrence and severity of sinusoidal obstruction syndrome after hematopoietic stem cell transplant in children.

Authors:  Carl J Rudebeck; Cécile Renard; Carine Halfon-Domenech; Marie Ouachée-Chardin; Michael Philippe; Frederic V Valla; Yves Bertrand; Mathilde Penel-Page
Journal:  EJHaem       Date:  2022-05-31

Review 7.  Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Khalil Ben Hassine; Madeleine Powys; Peter Svec; Miroslava Pozdechova; Birgitta Versluys; Marc Ansari; Peter J Shaw
Journal:  Front Pediatr       Date:  2021-12-10       Impact factor: 3.418

Review 8.  Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?

Authors:  M Y Eileen C van der Stoep; Lisa V E Oostenbrink; Robbert G M Bredius; Dirk Jan A R Moes; Henk-Jan Guchelaar; Juliette Zwaveling; Arjan C Lankester
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.